QP101 / Qurient - LARVOL DELTA

Enhancing potency through synergy: QP101, a novel HER2 targeting dual payload ADC shows potent preclinical activities (AACR-NCI-EORTC 2025) - "QP101 also demonstrates good tolerability in the preliminary toxicology study in non-human primates. These findings support further development of QP101 as a next-generation HER2 targeting ADC with improved efficacy and safety balance."

Preclinical • Oncology • CDK7 • HER-2 • TOP1